Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Gibson Oncology LLC currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are assigned to 1 distinct examiner, KENYON, JOHN S. The concentration of the portfolio is reflected in the use of 1 distinct art unit for all current prosecution activity. Because the company has 2 pending office actions, the workload is consolidated under 1 individual.
KENYON, JOHN S serves as the busiest examiner for the company, holding 2 pending office actions. This represents the entirety of the company's pending workload. The alignment of 1 distinct examiner across 1 distinct art unit suggests a focused prosecution footprint in the Biotechnology & Pharmaceuticals sector. Practitioners should note that the current examiner, KENYON, JOHN S, is responsible for the full scope of the company's active patent applications. This centralized structure means that any future filings in this area will likely encounter the same examiner and art unit environment.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KENYON, JOHN S | 2 | 79.7% | +18.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18618496 | Preparation and Uses of 7-Azaindenoisoquinolines | KENYON, JOHN S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18618496 | Preparation and Uses of 7-Azaindenoisoquinolines | KENYON, JOHN S | — |
| 18694168 | Preparation and Uses of 7-Azaindenoisoquinolines | KENYON, JOHN S | — |
| Art Unit | Apps |
|---|---|
| 1625 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18618496 | Preparation and Uses of 7-Azaindenoisoquinolines | KENYON, JOHN S | 1625 | §101§112 | Non-Final OA | — | Pending | Mar 27, 2024 |
| 18694168 | Preparation and Uses of 7-Azaindenoisoquinolines | KENYON, JOHN S | 1625 | §112DP | Non-Final OA | — | Pending | Mar 21, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial